Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: A pilot study

Journal of Rheumatology

Volumn 38, Issue 2, 2011, Pages 247-251

  Raterman, Hennie G ^a   Jamnitski, Anna ^b   Lems, Willem F ^a   Voskuyl, Alexandre E ^a   Dijkmans, Ben A C ^a   Bos, Wouter H ^b   Simsek, Suat ^a,c   Lips, Paul ^a   Van De Stadt, Rob J ^b   De Koning, Margret H M T ^b   Nurmohamed, Michael T ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c Location Alkmaar   (Netherlands)

Author keywords

Inflammation; Rheumatoid arthritis; Thyroid dysfunction; Tumor necrosis factor blocking agent

Indexed keywords

ADALIMUMAB; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; COMORBIDITY; DRUG EFFECT; FEMALE; FREE THYROXINE INDEX; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; PILOT PROJECTS; THYROID FUNCTION TESTS; THYROID GLAND; THYROTROPIN; THYROXINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551711376     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100488     Document Type: Article

References (19)

1. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000;43:522-30. (Pubitemid 30394942)
2. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571-9.
3. Raterman HG, van Halm VP, Voskuyl AE, Simsek S, Dijkmans BA, Nurmohamed MT. Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk. Ann Rheum Dis 2008;67:229-32. (Pubitemid 351183313)
4. Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006;33:2425-32. (Pubitemid 46067821)
5. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003;48:3308-19. (Pubitemid 37531897)
6. Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, et al. Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. Autoimmunity 2008;41:87-91.
7. Sabugo F, Liberman C, Niedmann JP, Soto L, Cuchacovich M. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol 2008;27:533-5. (Pubitemid 351404307)
8. van Lieshout AW, Creemers MC, Radstake TR, Elving LD, van Riel PL. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha. J Rheumatol 2008;35:938-9.
9. Diez JJ, Hernanz A, Medina S, Bayon C, Iglesias P. Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol 2002;57:515-21. (Pubitemid 35216303)
10. van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 1990;71:1567-72.
11. Miyakoshi H, Ohsawa K, Yokoyama H, Nagai Y, Ieki Y, Bando YI, et al. Exacerbation of hypothyroidism following tumor necrosis factor-alpha infusion. Intern Med 1992;31:200-3.
12. Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008;35:1972-7.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69 Suppl 1:i2-29.
15. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. Buscema M, Todd I, Deuss U, Hammond L, Mirakian R, Pujol-Borrell R, et al. Influence of tumor necrosis factor-alpha on the modulation by interferon-gamma of HLA class II molecules in human thyroid cells and its effect on interferon-gamma binding. J Clin Endocrinol Metab 1989;69:433-9. (Pubitemid 19208474)
17. Koenig RJ. Modeling the nonthyroidal illness syndrome. Curr Opin Endocrinol Diabetes Obes 2008;15:466-9.
18. Caturegli P, Kimura H. A nonclassical model of autoimmune hypothyroidism. Thyroid 2010;20:3-5.
19. Lazurova I, Benhatchi K, Rovensky J, Kozakova D, Wagnerova H, Tajtakova M, et al. Autoimmune thyroid disease and autoimmune rheumatic disorders: a two-sided analysis. Ann NY Acad Sci 2009;1173:211-6.